Logo

American Heart Association

  2
  0


Final ID: MDP358

Ectopic Fat Distribution and Adverse Muscle Composition in South Asians: Findings from the UK Biobank

Abstract Body (Do not enter title and authors here): Background: South Asians (SAs) have higher risk of diabetes and cardiovascular disease compared with other ethnicities; however, detailed analyses of their body composition profile (BCP), including ectopic fat, muscle mass and muscle quality are lacking. Such data may help explain the higher rate of type 2 diabetes (T2D) in SAs, as muscle mass and quality are increasingly recognized as being linked to long-term health outcomes.
Aims: This study utilizes imaging data from the UK Biobank cohort to compare body composition between SAs and white Europeans (EUR) to better understand ethnic differences in fat distribution and muscle composition.
Hypothesis: We predict that SAs will have higher levels of ectopic fat (visceral-, liver-, and muscle fat) than matched EUR, which may explain their higher rates of T2D.
Methods: Using UK Biobank imaging data captured by MRI, we compared body composition data in SAs (n=323) without T2D relative to age, sex, height and weight-matched EUR (matched 5:1 to SA group). We also compared BCP in 66 SAs with T2D versus matched EUR (matched 3:1 to SA group).
Results: SAs without T2D had higher overall levels of body fat compared to EUR (mean difference in: visceral adipose tissue 0.20 L; abdominal subcutaneous adipose tissue 0.93 L; liver fat 0.92 percentage points (pp); muscle fat infiltration (MFI) 0.59 pp, all p75th percentile and muscle volume <25th percentile) was more prevalent in SAs (19.9% vs 7.9%, p<0.001). Differences remained significant after further adjustment for prevalent disease, lifestyle and socioeconomic factors. SAs with T2D had similar BCP compared with matched EUR with T2D.
Conclusions: SAs without T2D have greater visceral, liver, and muscle fat accumulation, and lower muscle volume compared to EUR. These findings may underlie their greater risk for T2D and atherothrombotic outcomes, especially as BCP was similar when comparing SAs with T2D to matched EUR with T2D. Lifestyle modification to increase physical activity and reduce weight gain may offset cardiometabolic risks in SAs through favorable changes in body composition.
  • Tejani, Sanaa  ( UT Southwestern Medical Center , Frisco , Texas , United States )
  • Linge, Jennifer  ( AMRA Medical , Linköping , Sweden )
  • Neeland, Ian  ( University Hospitals - Case Western , Cleveland , Ohio , United States )
  • Rohatgi, Anand  ( UT SOUTHWESTERN , Dallas , Texas , United States )
  • Gill, Jason  ( University of Glasgow , Glasgow, Scotland , United Kingdom )
  • Dahlqvist Leinhard, Olof  ( AMRA Medical , Linköping , Sweden )
  • Sattar, Naveed  ( UNIVERSITY OF GLASGOW , Glasgow , United Kingdom )
  • Author Disclosures:
    Sanaa Tejani: DO NOT have relevant financial relationships | Jennifer Linge: No Answer | Ian Neeland: DO have relevant financial relationships ; Consultant:Novo Nordisk:Past (completed) ; Advisor:Eli Lilly and Co.:Past (completed) ; Speaker:Bayer Pharmaceuticals:Active (exists now) ; Speaker:Boehringer Ingelheim/Lilly Alliance:Active (exists now) | Anand Rohatgi: DO have relevant financial relationships ; Research Funding (PI or named investigator):CSL Behring:Active (exists now) ; Other (please indicate in the box next to the company name):Quest:Active (exists now) ; Consultant:Johnson and Johnson:Past (completed) ; Consultant:JP Morgan:Past (completed) ; Consultant:HDL Diagnostics:Active (exists now) ; Consultant:Raydel:Past (completed) | Jason Gill: DO NOT have relevant financial relationships | Olof Dahlqvist Leinhard: DO have relevant financial relationships ; Ownership Interest:AMRA Medical:Active (exists now) ; Independent Contractor:Novo Nordisk:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) | Naveed Sattar: DO have relevant financial relationships ; Consultant:Abbott Laboratories:Active (exists now) ; Research Funding (PI or named investigator):AZ, BI, Novartis, Roche:Active (exists now) ; Consultant:Sanofi:Past (completed) ; Consultant:Roche Diagnostics:Active (exists now) ; Consultant:Pfizer:Past (completed) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Novartis:Past (completed) ; Consultant:Menarini-Ricerche:Active (exists now) ; Consultant:Janssen:Past (completed) ; Consultant:Hanmi Pharmaceuticals:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:AbbVie:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Road to Cardiometabolic Disease: Exploring Biological and Social Mechanisms

Saturday, 11/16/2024 , 12:50PM - 02:15PM

Moderated Digital Poster Session

More abstracts on this topic:
A functional survey of postnatal heart maturation with in vivo Perturb-seq in spatial and temporal resolution

Wang Haofei, Liu Jiandong, Dong Yanhan, Shi Huitong, Colon Marazzano, Liu Xingyan, Farber Gregory, Qian Yunzhe, Anthony Nicholas, Qian Li

CASC15 lncRNA as a Mediator of Vascular Senescence in the Renin-Angiotensin System

Cunha Warlley, Martin Maria, Ahmed Ibrahim, Gomez Delphine, Espinosa-diez Cristina

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available